Celcuity Inc. (NASDAQ:CELC) on Tuesday reported detailed efficacy and safety findings from the PIK3CA-mutated cohort of its Phase 3 VIKTORIA-1 trial.
Gedatolisib Outperformed Comparator Regimen
Something went wrong.
According to the company, the gedatolisib-triplet regimen delivered a statistically significant improvement in progression-free survival compared with alpelisib plus fulvestrant.
Patients receiving the triplet therapy achieved a median progression-free survival of 11.1 months versus 5.6 months for the comparator arm.
